首页> 外文期刊>Glia >Non-PKC DAG/phorbol-ester receptor(s) inhibit complement receptor-3 and nPKC inhibit scavenger receptor-AI/II mediated myelin phagocytosis but cPKC, PI3K, and PLC gamma activate myelin phagocytosis by both
【24h】

Non-PKC DAG/phorbol-ester receptor(s) inhibit complement receptor-3 and nPKC inhibit scavenger receptor-AI/II mediated myelin phagocytosis but cPKC, PI3K, and PLC gamma activate myelin phagocytosis by both

机译:非PKC DAG /佛波酯酯受体抑制补体受体3和nPKC抑制清道夫受体AI / II介导的髓磷脂吞噬作用,但cPKC,PI3K和PLCγ均通过两者激活髓磷脂吞噬作用

获取原文
获取原文并翻译 | 示例
           

摘要

Complement-receptor-3 (CR3/MAC-1), scavenger-receptor-AI/ II (SRAI/II), and Fc gamma-receptor (Fc gamma R) can mediate myelin phagocytosis in macrophages and microglia. Paradoxically, after injury to CNS axons these receptors are expressed but myelin is not phagocytosed, suggesting that phagocytosis is subject to regulation between efficient and inefficient states. In the present work, we focus on CR3/MAC-1 and SRAI/II-mediated myelin phagocytosis. Phagocytosis by CR3/MAC-1 and SRAI/II was inhibited by cPKC inhibitor Go-6976, general-PKC inhibitors Ro-318220 and calphostin-C, and BAPTA/AM, which chelates intracellular Ca2+ required for cPKC activation. Signaling/activation by cPKC are thus suggested. PMA, which mimics diacylglycerol (DAG) as an activator of cPKC, novel-PKC (nPKC), and non-PKC DAG-driven molecule(s), produced a dose-dependent dual effect on phagocytosis by CR3/MAC-1 and SRAI/II, i.e., augmentation at low concentrations and inhibition at high concentrations. Inhibition of phagocytosis by CR3/MAC-1 was enhanced by combining inhibiting concentrations of PMA with PKC inhibitors Go-6976 or Ro-318220, suggesting inhibition by PMA/ DAG-driven non-PKC molecule(s). In contrast, inhibition of phagocytosis by SRAI/II was enhanced by combining inhibiting concentrations of PMA with cPKC inhibitor Go-6976 but not with general-PKC inhibitor Ro-318220, suggesting inhibition by nPKC. Phagocytosis by CR3/MAC-1 and SRAI/II was further inhibited by PI3K inhibitors wortmannin and LY-294002 and PLC gamma inhibitor U-73122. Altogether, our observations suggest that CR3/MAC-1 and SRAI/II-mediated myelin phagocytosis share activation by PI3K, PLC gamma and cPKC. The two differ, however, in that non-PKC DAG-driven molecule(s) inhibit CR3/MAC-1-mediated phagocytosis, whereas nPKC inhibit SRAI/II-mediated phagocytosis. Each of these signaling steps may be targeted for regulating CR3/ MAC-1 and/or SRAI/II-mediated phagocytosis between efficient and inefficient states. (C) 2005 Wiley-Liss, Inc.
机译:补体受体3(CR3 / MAC-1),清除剂受体AI / II(SRAI / II)和Fcγ受体(FcγR)可以介导巨噬细胞和小胶质细胞中的髓磷脂吞噬作用。矛盾的是,在中枢神经系统轴突损伤后,这些受体被表达,但髓磷脂并未被吞噬,这表明吞噬作用受到有效状态和无效状态之间的调节。在目前的工作中,我们专注于CR3 / MAC-1和SRAI / II介导的髓磷脂吞噬作用。 CR3 / MAC-1和SRAI / II的吞噬作用被cPKC抑制剂Go-6976,通用PKC抑制剂Ro-318220和calphostin-C以及BAPTA / AM抑制,它们螯合了cPKC激活所需的细胞内Ca2 +。因此建议通过cPKC进行信号传导/激活。 PMA模仿二酰基甘油(DAG)作为cPKC,新型PKC(nPKC)和非PKC DAG驱动分子的激活剂,它对CR3 / MAC-1和SRAI吞噬作用产生剂量依赖性双重作用/ II,即在低浓度下增强而在高浓度下抑制。通过将抑制浓度的PMA与PKC抑制剂Go-6976或Ro-318220结合使用,可增强CR3 / MAC-1对吞噬作用的抑制作用,表明受PMA / DAG驱动的非PKC分子抑制。相反,通过将抑制浓度的PMA与cPKC抑制剂Go-6976结合使用,而不与普通PKC抑制剂Ro-318220结合使用,可以增强SRAI / II对吞噬作用的抑制作用,这表明nPKC具有抑制作用。 PI3K抑制剂渥曼青霉素,LY-294002和PLCγ抑制剂U-73122进一步抑制了CR3 / MAC-1和SRAI / II的吞噬作用。总之,我们的观察结果表明,CR3 / MAC-1和SRAI / II介导的髓磷脂吞噬作用通过PI3K,PLCγ和cPKC共同激活。然而,两者的不同之处在于,非PKC DAG驱动的分子抑制CR3 / MAC-1介导的吞噬作用,而nPKC抑制SRAI / II介导的吞噬作用。这些信号传导步骤中的每一个都可以靶向于在有效和无效状态之间调节CR3 / MAC-1和/或SRAI / II介导的吞噬作用。 (C)2005 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号